Hayward, CA – According to filings with the U.S. Securities and Exchange Commission, Pulse Biosciences is raising $50,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Sandra Gardiner played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX System will be the first commercial product to harness the distinctive advantages of the Companys proprietary Nano-Pulse Stimulation (NPS) technology to treat a variety of applications for which an optimal solution remains unfulfilled. NPS technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To date, we own or have a license to more than 99 issued patents worldwide. With this growing patent portfolio surrounding our innovative technology, Pulse Biosciences seeks to aggressively realize the potential of Nano-Pulse Stimulation technology, building a rich pipeline of transformative commercial applications. From our first planned commercial product, the CellFX System, to our current ongoing clinical studies, and to the planned studies that fuel our pipeline, we see a clear path to the future as Pulse Biosciences brings the promise of NPS technology from the lab to lives of real patients today, and tomorrow.

To learn more about Pulse Biosciences, visit http://www.pulsebiosciences.com/

Contact:
Sandra Gardiner, Chief Financial Officer
510-906-4600
sgardiner@pulsebiosciences.com
https://www.linkedin.com/in/sandra-gardiner-0971853/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved